Billions for biotech: Oberland boosts biotech fund-raising past the $5B mark in a matter of weeks
Nobody appreciates nabbing a sweet late-stage investment deal more than the Oberland Capital team.
Operating in a highly competitive field, the group backed John Hood’s successful comeback play for fedratinib, offering up to $90 million a few years ago to get the application together. There was cash for Esperion in the lead-up to its commercialization work. A royalty deal pinned by GSK’s shingles vaccine helped Agenus along.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
